Mumbai, April 27 (Udaipur Kiran): Sun Pharma has announced the acquisition of US-based Organon for $11.75 billion (around Rs 1.10 lakh crore), marking the largest deal in the history of India’s pharmaceutical sector.
In an exchange filing, the company said the all-cash deal involves acquiring 100 percent stake in Organon at $14 per share.
Sun Pharma stated that the acquisition aligns with its strategy to expand its innovative medicines business and strengthen its presence in established brands and branded generics. The deal is also expected to help the company enter the biosimilars segment as a major global player.
Post-acquisition, the combined entity is expected to generate around $12.4 billion in revenue and rank among the top 25 global pharmaceutical companies. It will also enhance its position in women’s healthcare and biosimilars.
Organon, headquartered in New Jersey, operates in women’s health, biosimilars, and established medicines, with a portfolio of over 70 products and presence in more than 140 countries.
The transaction, approved by the boards of both companies, is subject to regulatory approvals and shareholder consent of Organon. It is expected to be completed in early 2027.
Sun Pharma plans to fund the deal through a mix of internal accruals and loans.
For the year ended December 2025, Organon reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion.
Following the announcement, shares of Sun Pharma surged over 7 percent. At around 10:50 am, the stock was trading near Rs 1,741.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
